BioLine RX

BLRX · TEL

$2.21+$0.2345 (+11.84%)TodayMarket closed · Oct 20, 6:52 PM ET

Prev close $1.98

Latest news

Press releaseOct 8, 7:00 AM ETPRNewswire
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
NewsSep 10, 8:06 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseSep 10, 7:00 AM ETPRNewswire
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
NewsSep 9, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseAug 31, 7:00 AM ETPRNewswire
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseAug 28, 8:00 AM ETPRNewswire
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
Press releaseAug 25, 7:00 AM ETPRNewswire
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
Press releaseJul 20, 7:00 AM ETPRNewswire
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
Press releaseJul 8, 7:00 AM ETPRNewswire
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
NewsMay 27, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseMay 27, 7:00 AM ETPRNewswire
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
Press releaseMay 22, 7:00 AM ETPRNewswire
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Press releaseMay 20, 7:00 AM ETPRNewswire
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
NewsMay 19, 6:28 PM ETVandana Singh
BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models
Press releaseMay 19, 7:00 AM ETPRNewswire
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
NewsMay 18, 5:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseApr 28, 7:00 AM ETPRNewswire
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Press releaseMar 26, 7:00 AM ETPRNewswire
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
NewsMar 23, 7:11 AM ET
Earnings Scheduled For March 23, 2026
Press releaseMar 23, 7:00 AM ETPRNewswire
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
Press releaseMar 16, 7:00 AM ETPRNewswire
BioLineRx to Report 2025 Annual Results on March 23, 2026
NewsFeb 26, 4:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseNov 24, 7:00 AM ETPRNewswire
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NewsNov 24, 6:11 AM ET
Earnings Scheduled For November 24, 2025
NewsNov 19, 4:07 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseNov 19, 3:00 AM ETBusiness Wire
Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors
Press releaseNov 18, 7:00 AM ETPRNewswire
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
Press releaseNov 17, 7:00 AM ETPRNewswire
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Press releaseSep 29, 7:00 AM ETPRNewswire
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
NewsSep 10, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsAug 19, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 14, 7:00 AM ETPRNewswire
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Press releaseAug 7, 7:00 AM ETPRNewswire
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
NewsJun 17, 8:00 AM ET
Where BioLine Rx Stands With Analysts
NewsMay 30, 2:55 PM ETAvi Kapoor
Dow Edges Higher; Dell Shares Fall After Q1 Results
NewsMay 30, 1:06 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

12 Health Care Stocks Moving In Wednesday's After-Market Session

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

12 Health Care Stocks Moving In Wednesday's After-Market Session

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

BioLineRx to Report First Quarter 2026 Results on May 27, 2026

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts

12 Health Care Stocks Moving In Monday's After-Market Session

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

Earnings Scheduled For March 23, 2026

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

BioLineRx to Report 2025 Annual Results on March 23, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For November 24, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session

Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Where BioLine Rx Stands With Analysts

Dow Edges Higher; Dell Shares Fall After Q1 Results

12 Health Care Stocks Moving In Friday's Intraday Session